Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.

Wenmin Chen,Jietao Lin,Ting Yang,Ze Xin Zhang,Lanting Tao,Zhiwei Xiao,Hanrui Chen,Xiangjun Qi,Lingling Sun,Yang Cao,Lizhu Lin

Integrative Cancer Therapies（2023）

Cited 0|Views9

No score

Abstract

The Ethics Committee of the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine approved the study protocol (approval no.: K2020151, 2021/08/19). The study will also be supervised and managed by the Ethics Committee.

Translated text

Key words

NSCLC,TCM,YFSJF,anloinib,combination therapy

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined